<DOC>
	<DOCNO>NCT00000371</DOCNO>
	<brief_summary>To characterize effect D-cycloserine augmentation antipsychotic treatment negative symptom , performance neurocognitive task , marker glutamatergic , dopaminergic serotonergic function serum cerebrospinal fluid . To determine negative symptom cognitive function improve time , improvement meaningfully impact quality life factor , correlate marker neuronal function , subpopulation identify accord response . Dysfunction glutamatergic neuronal system recently implicate pathophysiology schizophrenia base find non-competitive inhibitor NMDA receptor reproduce normal positive symptom , negative symptom , cognitive deficit schizophrenia . Furthermore , glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity , system central antipsychotic action typical neuroleptic . It believe enhance NMDA receptor function systemic treatment D-cycloserine , partial agonist glycine modulatory site NMDA receptor , reduce symptom schizophrenia . Sixty schizophrenic outpatient prominent , primary negative symptom treat antipsychotic medication randomly assign D-cycloserine placebo 6-month , fixed-dose trial . The primary outcome measure total score Scale Assessment Negative Symptoms ( SANS ) . A neuropsychological battery , emphasize test sensitive prefrontal cortical function , administer . Blood obtain several time point CSF obtain Week 8 assay concentration D-cycloserine , glutamate , HVA , 5HIAA .</brief_summary>
	<brief_title>Trial D-Cycloserine Schizophrenia</brief_title>
	<detailed_description>To characterize effect D-cycloserine augmentation antipsychotic treatment negative symptom , performance neurocognitive task , marker glutamatergic , dopaminergic , serotonergic function serum cerebrospinal fluid . To determine negative symptom cognitive function improve time , improvement meaningfully impact quality life factor , correlate marker neuronal function , subpopulation identify accord response . Dysfunction glutamatergic neuronal system recently implicate pathophysiology schizophrenia base find non-competitive inhibitor NMDA receptor reproduce normal positive symptom , negative symptom cognitive deficit schizophrenia . Furthermore , glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity , system central antipsychotic action typical neuroleptic . It believe enhance NMDA receptor function systemic treatment D-cycloserine , partial agonist glycine modulatory site NMDA receptor , reduce symptom schizophrenia . Sixty schizophrenic outpatient prominent , primary negative symptom treat antipsychotic medication randomly assign D-cycloserine placebo 6-month , fixed-dose trial . The primary outcome measure total score Scale Assessment Negative Symptoms ( SANS ) . A neuropsychological battery , emphasize test sensitive prefrontal cortical function , administer . Blood obtain several time point CSF obtain Week 8 assay concentration D-cycloserine , glutamate , HVA , 5HIAA .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Diagnosis Schizophrenia per DSM IV criterion Have treat least 6 month conventional neuroleptic Have prominent negative symptom define total score 40 great scale assessment negative symptom ( SANS ) Active alcohol drug abuse Unstable Medical Illness , seizure disorder , serious neurological disorder Pregnant Nursing Unable complete cognitive battery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Adult</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cycloserine</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Female</keyword>
	<keyword>Glutamic Acid</keyword>
	<keyword>Human</keyword>
	<keyword>Male</keyword>
	<keyword>Receptors , N-Methyl-D-Aspartate</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Serotonin</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Cycloserine -- *therapeutic use</keyword>
	<keyword>Dopamine -- blood</keyword>
	<keyword>Dopamine -- cerebrospinal fluid</keyword>
	<keyword>Glutamic Acid -- blood</keyword>
	<keyword>Glutamic Acid -- cerebrospinal fluid</keyword>
	<keyword>Serotonin -- blood</keyword>
	<keyword>Serotonin -- cerebrospinal fluid</keyword>
</DOC>